Contrasting Exelixis (EXEL) & Its Competitors
Exelixis (NASDAQ: EXEL) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Exelixis to related companies based on the strength of its valuation, earnings, profitability, dividends, institutional ownership, risk and analyst recommendations.
This table compares Exelixis and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
81.2% of Exelixis shares are held by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 5.1% of Exelixis shares are held by insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
Exelixis has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500. Comparatively, Exelixis’ peers have a beta of 5.95, meaning that their average share price is 495% more volatile than the S&P 500.
Valuation and Earnings
This table compares Exelixis and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Exelixis||$191.45 million||-$70.22 million||54.55|
|Exelixis Competitors||$284.28 million||$34.29 million||137.83|
Exelixis’ peers have higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent recommendations for Exelixis and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Exelixis presently has a consensus price target of $31.29, suggesting a potential upside of 17.04%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.68%. Given Exelixis’ peers stronger consensus rating and higher possible upside, analysts plainly believe Exelixis has less favorable growth aspects than its peers.
Exelixis peers beat Exelixis on 9 of the 13 factors compared.
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company’s CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company’s XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.
Receive News & Stock Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related stocks with our FREE daily email newsletter.